Track topics on Twitter Track topics that are important to you
GlycoVaxyn is a Zurich based biotechnology company. It was incorporated in November 2004 as a spin-off company of the ETH Zurich. Michael Wacker
Michael Wacker is a graduate in Biochemistry of the ETH in Zürich. Together with Prof. M. Aebi (Institute of Microbiology of the Swiss Federal Institute of Technology, ETH), he is the inventor of GlycoVaxyn’s technology, which he developed during his Ph.D. thesis and as a postdoc to its present, proprietary level.
As GlycoVaxyn’s Chief Scientific Officer, Michael is the key person responsible for the application of our technology for the development of products. He is also taking care of the research collaborations and contract research at the scientific level.
Phone: 41 44 680 13 31
Fax: 41 44 680 13 32
GlycoVaxyn is developing a broad portfolio of novel conjugate vaccines against common severe bacterial infections based on its unique, proprietary in-vivo glycosylation platform. ...
GlycoVaxyn is a Zurich based biotechnology company. It was incorporated in November 2004 as a spin-off company of the ETH Zurich. Michael WackerMichael Wacker is a graduate in Biochemistry of the ETH ...
We have published hundreds of GlycoVaxyn AG news stories on BioPortfolio along with dozens of GlycoVaxyn AG Clinical Trials and PubMed Articles about GlycoVaxyn AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GlycoVaxyn AG Companies in our database. You can also find out about relevant GlycoVaxyn AG Drugs and Medications on this site too.
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...